
BDX Stock Forecast & Price Target
BDX Analyst Ratings
Bulls say
Becton Dickinson is expected to see EPS growth through FY2030 thanks to their strong performance, new product launches, and the acquisition of Waters Corporation, while also planning to return cash to shareholders through repurchases and a $4 billion cash distribution. Despite potential risks and challenges, the company's continued focus on high-growth MedTech markets and their BD Excellence initiative bode well for their future success and drive in their stock price.
Bears say
Becton Dickinson is facing several key risks and headwinds in the near future, including the potential failure to achieve its milestones related to the separation of its Biosciences and Diagnostics divisions, ongoing headwinds and pressures in China, competition from larger and more specialized firms, potential changes in healthcare delivery and reimbursement, and potential global economic conditions that could negatively impact operations. Additionally, the company's financial performance in recent years has been affected by declines in certain segments and markets, such as Life Sciences and China, which could continue to be a drag on future growth.
This aggregate rating is based on analysts' research of Becton, Dickinson and Co. and is not a guaranteed prediction by Public.com or investment advice.
BDX Analyst Forecast & Price Prediction
Start investing in BDX
Order type
Buy in
Order amount
Est. shares
0 shares